How we manage patients with hereditary haemochromatosis.

Eva Rombout-Sestrienkova, Marian G J van Kraaij, Ger H Koek

Journal: British journal of haematology 2017;175(5):759-770

PMID: 27723100

Abstract

A number of disorders cause iron overload: some are of genetic origin, such as hereditary haemochromatosis, while others are acquired, for instance due to repeated transfusions. This article reviews the treatment options for hereditary haemochromatosis, with special attention to the use of erythrocytapheresis. In general, therapy is based on the removal of excess body iron, for which ferritin levels are used to monitor the effectiveness of treatment. For many decades phlebotomy has been widely accepted as the standard treatment. Recent publications suggest that erythrocytapheresis, as a more individualized treatment, can provide a good balance between effectiveness, tolerability and costs. Other treatments like oral chelators and proton pomp inhibitors, which are used in selected patients, create the possibility to further individualize treatment of hereditary haemochromatosis. In the future, hepcidin-targeted therapy could provide a more fundamental approach to treatment.

© 2016 John Wiley & Sons Ltd.

Address: Division of Gastroenterology & Hepatology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.; Department of Transfusion Medicine, Sanquin Blood Supply, Amsterdam, the Netherlands.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.